The Food and Drug Administration faces potential legal pushback regarding its plan to mandate Generally Recognized As Safe, or GRAS, notifications. Todd Harrison, a partner at Venable LLP, argues that the Federal Food, Drug and Cosmetic Act does not explicitly require companies to submit these filings to the agency. His analysis highlights that the FDA previously stated it lacked the authority to demand such notifications, creating a contradiction that may trigger significant judicial scrutiny.
Industry experts warn that if this policy moves forward, it introduces substantial uncertainty for ingredient suppliers and businesses within the functional food and beverage sector. Harrison suggests that if the proposal stands, it could disrupt operations for firms that rely on current self-affirmed safety determinations. There is also concern regarding how the agency plans to manage the administrative load of reviewing thousands of botanical extracts and ingredients under a new mandatory system.
Instead of a rigid mandate, some suggest the agency focus on developing a centralized database to track ingredients within the food supply. This approach would allow regulators to target their limited resources toward actual safety risks rather than administrative processing. The legal vulnerability of the agency's position is further intensified by the 2024 Loper Bright decision from the Supreme Court, which restricts the extent to which courts defer to agency interpretations of statutes.
Companies currently utilizing self-affirmed GRAS status remain in a precarious position as they await clarification on the proposed changes. The lack of a clear remedy or final decision process within the FDA’s current proposal leaves many businesses exposed to commercial instability. Stakeholders continue to monitor the situation to determine if the FDA can provide a sound legal rationale for this regulatory shift.